

Immunization Safety Review
Public Access Records Office Deposit
Meeting 2, March 8-10, 2001 (as of 5/16/01)

- Rec# 787. 1998. Autism, inflammatory bowel disease, and MMR vaccine. *Lancet* 351:611-612.
- Rec# 225. 1998. MMR vaccine coverage falls after adverse publicity. *Commun Dis Rep CDR Wkly* 8(5):41, 44.
- Rec# 783. January 27, 2001. Shots Fired. [Online]. Available:
www.economist.com/printerfriendly.cfm?Story_ID=486792 [accessed February, 2001].
- Rec# 390. Afzal MA, Armitage E, Begley J, et al. 1998. Absence of detectable measles virus genome sequence in inflammatory bowel disease tissues and peripheral blood lymphocytes. *J Med Virol* 55(3):243-249.
- Rec# 90. Afzal MA, Minor PD, Begley J, et al. 1998. Absence of measles-virus genome in inflammatory bowel disease [letter]. *Lancet* 351(9103):646-647.
- Rec# 382. Afzal MA, Minor PD, Schild GC. 2000. Clinical safety issues of measles, mumps and rubella vaccines. *Bull World Health Organ* 78(2):199-204.
- Rec# 465. Aitken K. Presentation to Immunization Safety Review Committee. Is There Evidence of Recent Changes in the Patterns of Clinical Presentation of Autistic Disorder?: March 8, 2001; Washington, DC.
- Rec# 385. Akobeng AK, Thomas AG. 1999. Inflammatory bowel disease, autism, and the measles, mumps, and rubella vaccine. *J Pediatr Gastroenterol Nutr* 28(3):351-2.
- Rec# 777. Anderson P. 1999. Another media scare about MMR vaccine hits Britian. *BMJ* 18:1578.
- Rec# 407. Atkinson WL, Hadler SC, Redd SB, Orenstein WA. 1992. Measles surveillance--United States, 1991. *Mor Mortal Wkly Rep CDC Surveill Summ* 41(6):1-12.
- Rec# 408. Atkinson WL, Orenstein WA, Krugman S. 1992. The resurgence of measles in the United States, 1989-1990. *Annu Rev Med* 43(6):451-63.
- Rec# 147. Babad HR, Nokes DJ, Gay NJ, Miller E, Morgan-Capner P, Anderson RM. 1995. Predicting the impact of measles vaccination in England and Wales: model validation and analysis of policy options [published erratum appears in *Epidemiol Infect* 1995 Aug;115(1):213]. *Epidemiol Infect* 114(2):319-44.
- Rec# 281. Bailey A, Le Couteur A, Gottesman I, et al. 1995. Autism as a strongly genetic disorder: evidence from a British twin study. *Psychol Med* 25(1):63-77.
- Rec# 123. Barton M, Volkmar F. 1998. How commonly are known medical conditions associated with autism? *J Autism Dev Disord* 28(4):273-8.
- Rec# 321. Bauman M. 1999. Autism: Clinical features and neurobiological observations. Tager-Flusberg H. *Neurodevelopmental Disorders*. Cambridge, MA: The MIT Press. Pp. 383-399.
- Rec# 515. BBC News. March 7, 2001. Big increase in mumps. [Online]. Available:
http://news.bbc.co.uk/hi/english/health/newsid_1207000/1207071.stm [accessed March 7, 2001].
- Rec# 495. Bell P, Bell E. Letter to Immunization Safety Review Committee. 2001 Mar 6.
- Rec# 497. Bernard S. Letter to Immunization Safety Review Committee. 2001 Mar 5.
- Rec# 489. Bernier R, Chu S, Wharton M. Letter to Immunization Safety Review Committee. 2001.

- Rec# 494. Birt E. Letter to Immunization Safety Review Committee. 2001 Mar 6.
- Rec# 393. Bolton PF, Murphy M, Macdonald H, Whitlock B, Pickles A, Rutter M. 1997. Obstetric complications in autism: consequences or causes of the condition? *J Am Acad Child Adolesc Psychiatry* 36(2):272-81.
- Rec# 509. Boyle C. April 6, 2000. Testimony before the Committee on Government Reform; US House of Representatives. [Online]. Available: <http://www.cdc.gov/od/wash/cb2k0406.htm> [accessed February 14, 2001].
- Rec# 160. Bristol MM, Cohen DJ, Costello EJ, et al. 1996. State of the science in autism: report to the National Institutes Health. *J Autism Dev Disord* 26(2):121-54.
- Rec# 460. Bristol-Power M. Presentation to Immunization Safety Review Committee. Etiology of Autism: March 8, 2001; Washington, DC.
- Rec# 505. Burton D. April 6, 2000. Opening Statement to "Autism: Present Challenges, Future Needs - why the increased rates?". [Online]. Available: http://www.house.gov/reform/hearings/healthcare/00.06.04/opening_statement.htm [accessed December 21, 2000].
- Rec# 506. Burton D. Letter to Honorable Donna Shalala. 2000 May 16.
- Rec# 217. California Health and Human Services Agency, Department of Developmental Services. 1999. *Changes in the Population of Persons With Autism and Pervasive Developmental Disorders in California's Developmental Services System: 1987 Through 1998* .
- Rec# 406. Camargo MC , Cassio de Moraes J , Souza VA , Matos MR , Pannuti CS. 2000. Predictors Related to the Occurrence of a Measles Epidemic in the City of San Paolo in 1997. *REv Panam Salud Publica/Pan Am J Public Health* 7(6):359-365.
- Rec# 789. Carbone K. Presentation to the Institute of Medicine Vaccine Safety Forum. IOM Vaccine Safety Forum: 1998; Washington, DC.
- Rec# 496. Catlin M. Letter to Immunization Safety Review Committee. 2001 Feb 26.
- Rec# 220. CDC. 2000. *Prevalence of Autism in Brick Township, NJ, 1998: Community Report* .
- Rec# 89. Chadwick N, Bruce IJ, Schepelmann S, Pounder RE, Wakefield AJ. 1998. Measles virus RNA is not detected in inflammatory bowel disease using hybrid capture and reverse transcription followed by the polymerase chain reaction. *J Med Virol* 55(4):305-11.
- Rec# 42. Chen RT, DeStefano F. 1998. Vaccine adverse events: Causal or coincidental? *Lancet* 351(9103):611-612.
- Rec# 786. Cobain I. Move to outlaw single MMR jabs. *The Times London*. January 13, 2001.
- Rec# 454. Communicable Disease Report. 1998. Sentinel surveillance shows small decline in MMR coverage. *Communicable Disease Report CDR Weekly* 8(36):319-320.
- Rec# 780. Communicable Disease Report. 1999. Fall in MMR vaccine coverage reported as further evidence of vaccine safety is published. *Commun Dis Rep CDR Wkly* 9(26):227-230.
- Rec# 779. Communicable Disease Report. 1999. MMR vaccine coverage at 24 months stabilises in the UK. *Commun Dis Rep CDR Wkly* 9(13):113-116.
- Rec# 778. Communicable Disease Report. 1999. MMR Vaccine Coverage Falls in the United Kingdom. *Commun*

Dis Rep CDR Wkly 9(5):37.

- Rec# 781. Communicable Disease Report. 1999. MMR vaccine coverage shows signs of recovery. *Commun Dis Rep CDR Wkly* 9(39):345.
- Rec# 782. Communicable Disease Report. 2000. Outbreaks of measles in communities with low vaccine coverage. *Commun Dis Rep CDR Wkly* 10(4):29-32.
- Rec# 424. Communicable Disease Report. 2001. MMR vaccination coverage in the United Kingdom. *Communicable Disease Report CDR Weekly* 11(4).
- Rec# 392. Curry CJ, Stevenson RE, Aughton D, et al. 1997. Evaluation of mental retardation: recommendations of a Consensus Conference: American College of Medical Genetics. *Am J Med Genet* 72(4):468-77.
- Rec# 490. Dales L. Letter to Immunization Safety Review Committee. 2001.
- Rec# 512. Dales L, Hammer SJ, Smith N. 2001. Time trends in autism and in MMR immunization coverage in California. *JAMA* 285(9):1183-1185.
- Rec# 464. Danielson L. Presentation to Immunization Safety Review Committee. Counting Children With Autism: March 8, 2001; Washington, DC.
- Rec# 125. Daszak P, Purcell M, Lewin J, Dhillon AP, Pounder RE, Wakefield AJ. 1997. Detection and comparative analysis of persistent measles virus infection in Crohn's disease by immunogold electron microscopy. *J Clin Pathol* 50(4):299-304.
- Rec# 142. Davis RL, Marcuse E, Black S, et al. 1997. MMR2 immunization at 4 to 5 years and 10 to 12 years of age: a comparison of adverse clinical events after immunization in the Vaccine Safety Datalink project. The Vaccine Safety Datalink Team [see comments]. *Pediatrics* 100(5):767-71.
- Rec# 513. DeWilde S., Carey IM, Richards N, Hilton SR, Cook DG. 2001. Do children who become autistic consult more often after MMR vaccination? *British Journal of General Practice* 51(464):226-7.
- Rec# 155. Duclos P, Ward BJ. 1998. Measles vaccines: a review of adverse events. *Drug Saf* 19(6):435-54.
- Rec# 201. Ekobom A, Daszak P, Kraaz W, Wakefield AJ. 1996. Crohn's disease after in-utero measles virus exposure [see comments]. *Lancet* 348(9026):515-7.
- Rec# 98. Ekobom A, Wakefield AJ, Zack M, Adami HO. 1994. Perinatal measles infection and subsequent Crohn's disease [see comments]. *Lancet* 344(8921):508-10.
- Rec# 403. Elliman D, Bedford H. 2001. MMR vaccine: the continuing saga. Current concerns are idiosyncratic: most reviews have confirmed the vaccine's safety. *BMJ* 322(7280):183-184.
- Rec# 785. Fauntleroy G. Stealth Viruses. *The New Mexican*. January 29, 2001.
- Rec# 141. Feeney M, Ciegg A, Winwood P, Snook J. 1997. A case-control study of measles vaccination and inflammatory bowel disease. The East Dorset Gastroenterology Group. *Lancet* 350(9080):764-6.
- Rec# 228. Filipek PA, Accardo PJ, Baranek GT, et al. 1999. The screening and diagnosis of autistic spectrum disorders. *J Autism Dev Disord* 29(6):439-84.
- Rec# 143. Fine PE. 1993. Herd immunity: history, theory, practice. *Epidemiol Rev* 15(2):265-302.
- Rec# 462. Fombonne E. Presentation to Immunization Safety Review Committee. Epidemiological Slide Set: March

- 8, 2001; Washington, DC.
- Rec# 198. Fombonne E. 1996. Is the prevalence of autism increasing? [editorial]. *J Autism Dev Disord* 26(6):673-6.
- Rec# 197. Fombonne E. 1998. Inflammatory bowel disease and autism [letter]. *Lancet* 351(9107):955.
- Rec# 135. Fombonne E. 1999. The epidemiology of autism: a review. *Psychol Med* 29(4):769-86.
- Rec# 369. Fombonne E. 1999. Are measles infections or measles immunizations linked to autism? *J Autism Dev Disord* 29(4):349-50.
- Rec# 776. Fombonne E. 2001. The epidemiology of autism and related pervasive developmental disorders. Lord C , ed. *Educating Children With Autism*. Washington DC: National Academy of Sciences Press.
- Rec# 216. Fombonne E. 2001. Is there an epidemic of autism? *Pediatrics* :411-413.
- Rec# 463. Fombonne E. Presentation to Immunization Safety Review Committee. New Studies: March 8, 2001; Washington, DC. 2001.
- Rec# 91. Fombonne E, Du Mazaubrun C, Cans C, Grandjean H. 1997. Autism and associated medical disorders in a French epidemiological survey. *J Am Acad Child Adolesc Psychiatry* 36(11):1561-9.
- Rec# 499. Gallup R. Letter to Immunization Safety Review Committee. 2001 Mar 3.
- Rec# 156. Gangarosa EJ, Galazka AM, Wolfe CR, et al. 1998. Impact of anti-vaccine movements on pertussis control: the untold story. *Lancet* 351(9099):356-61.
- Rec# 146. Gay NJ, Hesketh LM, Morgan-Capner P, Miller E. 1995. Interpretation of serological surveillance data for measles using mathematical models: implications for vaccine strategy. *Epidemiol Infect* 115(1):139-56.
- Rec# 189. Gillberg C. 1984. Infantile autism and other childhood psychoses in a Swedish urban region. Epidemiological aspects. *J Child Psychol Psychiatry* 25(1):35-43.
- Rec# 378. Gillberg C. 1995. Endogenous opioids and opiate antagonists in autism: brief review of empirical findings and implications for clinicians. *Dev Med Child Neurol* 37(3):239-45.
- Rec# 391. Gillberg C. 1998. Chromosomal disorders and autism. *J Autism Dev Disord* 28(5):415-25.
- Rec# 161. Gillberg C, Coleman M. 1996. Autism and medical disorders: A review of the literature. *Dev Med Child Neurol* 38(3):191-202.
- Rec# 133. Gillberg C, Heijbel H. 1998. MMR and autism. *Autism* 2:423-424.
- Rec# 182. Gillberg C, Steffenburg S, Schaumann H. 1991. Is autism more common now than ten years ago? *Br J Psychiatry* 158:403-9.
- Rec# 129. Gillberg C, Wing L. 1999. Autism: not an extremely rare disorder. *Acta Psychiatr Scand* 99(6):399-406.
- Rec# 377. Goldenthal KL, Burns DL, McVittie LD, Lewis BP, Williams JC. 1995. Overview--combination vaccines and simultaneous administration. Past, present, and future. *Ann NY Acad Sci* 754(3):xi-xv.
- Rec# 298. Gonzalez-Dunia D, Watanabe M, Syan S, Mallory M, Masliah E, De La Torre JC. 2000. Synaptic pathology in Borna disease virus persistent infection. *J Virol* 74(8):3441-8.
- Rec# 410. Grenfell BT , Bolker BM. 1994. Population Dynamics and Measles. *Parasitic and Infectious Diseases*.

Academic Press.

- Rec# 94. Haga Y, Funakoshi O, Kuroe K, et al. 1996. Absence of measles viral genomic sequence in intestinal tissues from Crohn's disease by nested polymerase chain reaction . *Gut* 38(2):211-5.
- Rec# 498. Halker A. Letter to Immunization Safety Review Committee. 2001 Mar 6.
- Rec# 501. Halsey NA. Letter to Immunization Safety Review committee. 2001.
- Rec# 166. Hillman RE, Kanafani N, Takahashi TN, Miles JH. 2000. Prevalence of autism in Missouri: changing trends and the effect of a comprehensive state autism project. *Mo Med* 97(5):159-63.
- Rec# 296. Hirano A. 1992. Subacute sclerosing panencephalitis virus dominantly interferes with replication of wild-type measles virus in a mixed infection: implication for viral persistence. *J Virol* 66(4):1891-8.
- Rec# 174. Honda H, Shimizu Y, Misumi K, Niimi M, Ohashi Y. 1996. Cumulative incidence and prevalence of childhood autism in children in Japan. *Br J Psychiatry* 169(2):228-35.
- Rec# 402. Hornig M, Weissenbock H, Horscroft N, Lipkin WI. 1999. An infection-based model of neurodevelopmental damage. *Proc Natl Acad Sci U S A* 96(21):12102-7.
- Rec# 784. Hurwitz EL. Parents should know both the benefits and risks of vaccinations. *Los Angeles Times*. January 30, 2001.
- Rec# 219. Iizuka M, Ito H, Chiba M, Shirasaka T, Watanabe S. 2000. The MMR question. *Lancet* 356(9224):160.
- Rec# 97. Iizuka M, Nakagomi O, Chiba M, Ueda S, Masamune O. 1995. Absence of measles virus in Crohn's disease [letter]. *Lancet* 345(8943):199.
- Rec# 376. Insel RA. 1995. Potential alterations in immunogenicity by combining or simultaneously administering vaccine components. *Ann N Y Acad Sci* 754(3):35-47.
- Rec# 468. IOM (Institute of Medicine). Transcript of 2001 March 8 Meeting. March 8, 2001; Washington, DC.
- Rec# 150. Jorde LB, Mason-Brothers A, Waldmann R, et al. 1990. The UCLA-University of Utah epidemiologic survey of autism: genealogical analysis of familial aggregation. *Am J Med Genet* 36(1):85-8.
- Rec# 168. Kadesjo B, Gillberg C, Hagberg B. 1999. Brief report: autism and Asperger syndrome in seven-year-old children: a total population study. *J Autism Dev Disord* 29(4):327-31.
- Rec# 196. Kawashima H, Mori T, Kashiwagi Y, Takekuma K, Hoshika A, Wakefield A. 2000. Detection and sequencing of measles virus from peripheral mononuclear cells from patients with inflammatory bowel disease and autism. *Dig Dis Sci* 45(4):723-9.
- Rec# 518. Kaye JA, del Mar Melero-Montes M, Jick H. 2001. Mumps, measles, and rubella vaccine and the incidence of autism recorded by general practitioners: a time trend analysis. *BMJ* 322(7284):460-3.
- Rec# 459. Kemper T. Presentation to Immunization Safety Review Committee. Neuroanatomic Observations of the Brain in Autism: March 8, 2001; Washington, DC.
- Rec# 105. Kemper TL, Bauman M. 1998. Neuropathology of infantile autism. *J Neuropathol Exp Neurol* 57(7):645-52.
- Rec# 398. Lerman SJ, Bollinger M, Brunken JM. 1981. Clinical and serologic evaluation of measles, mumps, and

- rubella (HPV-77:DE-5 and RA 27/3) virus vaccines, singly and in combination. *Pediatrics* 68(1):18-22.
- Rec# 324. Lewin J, Dhillon AP, Sim R, Mazure G, Pounder RE, Wakefield AJ. 1995. Persistent measles virus infection of the intestine: confirmation by immunogold electron microscopy. *Gut* 36(4):564-9.
- Rec# 491. Lurie P. Letter to Immunization Safety Review Committee. 2001Mar 2.
- Rec# 453. Medical Control Agency , Working Party on MMR Vaccine. 1999. Report of the Working Party on MMR Vaccine.
- Rec# 452. Medicines Control Agency , Department of Health . 2001. Combined measles, mumps and rubella vaccines: Response to Issues raised in papers published in "Adverse Drug Reactions and Toxicological Review, volume 19 no 4, 2000.
- Rec# 158. Metcalf J. 1998. Is measles infection associated with Crohn's disease? [editorial; comment]. *BMJ* 316(7126):166.
- Rec# 139. Miller D, Wadsworth J, Diamond J, Ross E. 1997. Measles vaccination and neurological events [letter; comment]. *Lancet* 349(9053):730-1.
- Rec# 492. Miller E, Farrington CP, Taylor B. Letter to Immunization Safety Review Committee. 2001 Mar 6.
- Rec# 96. Miyamoto H, Tanaka T, Kitamoto N, Fukuda Y, Shimoyama T. 1995. Detection of immunoreactive antigen, with a monoclonal antibody to measles virus, in tissue from a patient with Crohn's disease. *J Gastroenterol* 30(1):28-33.
- Rec# 99. Morris DL, Montgomery SM, Thompson NP, Ebrahim S, Pounder RE, Wakefield AJ. 2000. Measles vaccination and inflammatory bowel disease: a national British Cohort Study.[In Process Citation]. *Am J Gastroenterol* 95(12):3507-12.
- Rec# 374. Nagamitsu S, Matsuishi T, Kisa T, et al. 1997. CSF beta-endorphin levels in patients with infantile autism. *J Autism Dev Disord* 27(2):155-63.
- Rec# 503. National Institute of Child Health and Human Development. 2000. Collaborative Programs of Excellence in Autism. [Online]. Available: <http://156.40.88.3/autism/cpea.cfm> [accessed March 28, 2001].
- Rec# 502. National Institute of Mental Health. 1999. Autism Research at the National Institute of Mental Health. [Online]. Available: <http://www.nimh.nih.gov/publicat/autismresfact.cfm> [accessed March 28, 2001].
- Rec# 181. Nelson KB. 1991. Prenatal and perinatal factors in the etiology of autism. *Pediatrics* 87(5 Pt 2):761-6.
- Rec# 488. Nelson KB. Presentation to Immunization Safety Review Committee. Neurologic Diagnosis In Study Subjects: March 8, 2001; Washington, DC.
- Rec# 211. Nicoll A, Elliman D, Ross E. 1998. MMR vaccination and autism 1998. *BMJ* 316(7133):715-6.
- Rec# 409. Orenstein WA , Markowitz LE , Atkinson WL , Hinman AR. 1993. The experience with measles in the United States. Kurstak E, Editor. *Measles and Poliomyelitis*. Pp. 23-35.
- Rec# 140. Pardi DS, Tremaine WJ, Sandborn WJ, et al. 2000. Early measles virus infection is associated with the development of inflammatory bowel disease [see comments]. *Am J Gastroenterol* 95(6):1480-5.
- Rec# 154. Pardi DS, Tremaine WJ, Sandborn WJ, Loftus EV Jr, Poland GA, Melton LJ 3rd. 1999. Perinatal exposure to measles virus is not associated with the development of inflammatory bowel disease. *Inflamm Bowel Dis* 5(2):104-6.

- Rec# 116. Patja A, Davidkin I, Kurki T, Kallio MJ, Valle M, Peltola H. 2000. Serious adverse events after measles-mumps-rubella vaccination during a fourteen-year prospective follow-up. *Pediatr Infect Dis J* 19(12):1127-34.
- Rec# 163. Peltola H, Heinonen OP. 1986. Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-blind placebo-controlled trial in twins. *Lancet* 1(8487):939-42.
- Rec# 124. Peltola H, Patja A, Leinikki P, Valle M, Davidkin I, Paunio M. 1998. No evidence for measles, mumps, and rubella vaccine-associated inflammatory bowel disease or autism in a 14-year prospective study [letter]. *Lancet* 351(9112):1327-8.
- Rec# 381. Petrovic M, Roberts R, Ramsay M. 2001. Second dose of measles, mumps, and rubella vaccine: questionnaire survey of health professionals. *BMJ* 322(7278):82-85.
- Rec# 394. Piven J, Simon J, Chase GA, et al. 1993. The etiology of autism: pre-, peri- and neonatal factors. *J Am Acad Child Adolesc Psychiatry* 32(6):1256-63.
- Rec# 290. Plata-Salaman CR, Ilyin SE, Gayle D, Romanovitch A, Carbone KM. 1999. Persistent Borna disease virus infection of neonatal rats causes brain regional changes of mRNAs for cytokines, cytokine receptor components and neuropeptides. *Brain Res Bull* 49(6):441-51.
- Rec# 288. Pletnikov MV, Rubin SA, Schwartz GJ, Carbone KM, Moran TH. 2000. Effects of neonatal rat Borna disease virus (BDV) infection on the postnatal development of the brain monoaminergic systems. *Brain Res Dev Brain Res* 119(2):179-85.
- Rec# 291. Pletnikov MV, Rubin SA, Schwartz GJ, Moran TH, Sobotka TJ, Carbone KM. 1999. Persistent neonatal Borna disease virus (BDV) infection of the brain causes chronic emotional abnormalities in adult rats. *Physiol Behav* 66(5):823-31.
- Rec# 292. Pletnikov MV, Rubin SA, Vasudevan K, Moran TH, Carbone KM. 1999. Developmental brain injury associated with abnormal play behavior in neonatally Borna disease virus-infected Lewis rats: a model of autism. *Behav Brain Res* 100(1-2):43-50.
- Rec# 413. Plotkin SA. 1999. Chapter 17: Rubella Vaccine. Plotkin SA, Orenstein WA, Editors. *Vaccines*. Third ed. Philadelphia: W.B. Saunders Co.
- Rec# 412. Plotkin SA, Wharton M. 1999. Chapter 13: Mumps Vaccine. Plotkin SA, Orenstein WA, Editors. *Vaccines*. Third ed. Philadelphia: W.B. Saunders Co.
- Rec# 411. Redd SC, Markowitz LE, Katz SL. 1999. Chapter 12: Measles Vaccine. Plotkin SA, Orenstein WA, Editors. *Vaccines*. Third ed. Philadelphia: W.B. Saunders Co.
- Rec# 152. Ritvo ER, Freeman BJ, Pingree C, et al. 1989. The UCLA-University of Utah epidemiologic survey of autism: prevalence. *Am J Psychiatry* 146(2):194-9.
- Rec# 151. Ritvo ER, Jorde LB, Mason-Brothers A, et al. 1989. The UCLA-University of Utah epidemiologic survey of autism: recurrence risk estimates and genetic counseling. *Am J Psychiatry* 146(8):1032-6.
- Rec# 293. Rubin SA, Bautista JR, Moran TH, Schwartz GJ, Carbone KM. 1999. Viral teratogenesis: brain developmental damage associated with maturation state at time of infection. *Brain Res Dev Brain Res* 112(2):237-44.
- Rec# 284. Rutter M, Bailey A, Bolton P, Le Couteur A. 1994. Autism and known medical conditions: myth and substance. *J Child Psychol Psychiatry* 35(2):311-22.

- Rec# 405. Rutter M , Bailey A , Simonoff E , Pickles A. 1997. Genetic Influences and Autism. Cohen D , Volkmar F, Editors. *Handbook of Autism and Pervasive Developmental Disorders*. Second Edition ed. New York: John Wiley. Pp. 370-387.
- Rec# 788. Sabra A BJCA. 1998. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. *Lancet*. 1998 Feb 28;351(9103):637-41 28(351):234-235.
- Rec# 510. Salisbury D. January 22, 2001. Parents have no cause for alarm as this scare is based on flawed research. [Online]. Available: http://www.independent.co.uk/news/UK/Health/2001-01/for_220101.shtml [accessed March 7, 2001].
- Rec# 379. Sandman CA, Barron JL, Demet EM, Chicz-Demet A, Rothenberg SJ, Zea FJ. 1990. Opioid peptides and perinatal development: is beta-endorphin a natural teratogen? Clinical implications. *Ann N Y Acad Sci* 579(3):91-108.
- Rec# 299. Sauder C, de la Torre JC. 1999. Cytokine expression in the rat central nervous system following perinatal Borna disease virus infection. *J Neuroimmunol* 96(1):29-45.
- Rec# 375. Scifo R, Cioni M, Nicolosi A, et al. 1996. Opioid-immune interactions in autism: behavioural and immunological assessment during a double-blind treatment with naltrexone. *Ann Ist Super Sanita* 32(3):351-9.
- Rec# 372. Selin LK, Lin MY, Kraemer KA, et al. 1999. Attrition of T cell memory: selective loss of LCMV epitope-specific memory CD8 T cells following infections with heterologous viruses. *Immunity* 11(6):733-42.
- Rec# 320. Selin LK, Varga SM, Wong IC, Welsh RM. 1998. Protective heterologous antiviral immunity and enhanced immunopathogenesis mediated by memory T cell populations. *J Exp Med* 188(9):1705-1715.
- Rec# 508. Shalala D. Letter to Waxman H. Rep. 2000 Aug 22.
- Rec# 373. Sher L. 1997. Autistic disorder and the endogenous opioid system. *Med Hypotheses* 48(5):413-4.
- Rec# 514. Smeeth L , Hall AJ , Fombonne E , Rodrigues LC , Huang X , Smith PG. 2001. A case-control study of autism and mumps-measles-rubella vaccination using the general practice research database: design and methodology. *BMC Public Health* 1(1):2.
- Rec# 500. Spitzer W. Letter to Immunization Safety Review Committee. 2001 Feb 28.
- Rec# 170. Sponheim E, Skjeldal O. 1998. Autism and related disorders: epidemiological findings in a Norwegian study using ICD-10 diagnostic criteria. *J Autism Dev Disord* 28(3):217-27.
- Rec# 180. Steffenburg S. 1991. Neuropsychiatric assessment of children with autism: a population-based study. *Dev Med Child Neurol* 33(6):495-511.
- Rec# 466. Stoto M. Presentation to Immunization Safety Review Committee. Epidemiologic Studies of MMR Vaccine and Autism: March 8, 2001; Washington, DC.
- Rec# 487. Stoto MA, Clery SD, Foster VB. Epidemiologic studies of MMR Vaccine and Autism. 2001.
- Rec# 165. Tanguay PE. 2000. Pervasive developmental disorders: a 10-year review. *J Am Acad Child Adolesc Psychiatry* 39(9):1079-95.
- Rec# 43. Taylor B, Miller E, Farrington CP, et al. 1999. Autism and measles, mumps, and rubella vaccine: No epidemiological evidence for a causal association. *Lancet* 353(9169):2026-2029.

- Rec# 214. Thomas DR, Salmon RL, King J. 1998. Rates of first measles-mumps-rubella immunisation in Wales (UK). *Lancet* 351(9120):1927.
- Rec# 323. Thompson NP, Fleming DM, Pounder RE, Wakefield AJ. 1996. Crohn's disease, measles, and measles vaccination: a case-control failure. *Lancet* 347(8996):263.
- Rec# 110. Thompson NP, Montgomery SM, Pounder RE, Wakefield AJ. 1995. Is measles vaccination a risk factor for inflammatory bowel disease? [see comments]. *Lancet* 345(8957):1071-4.
- Rec# 103. Thompson NP, Montgomery SM, Wadsworth ME, Pounder RE, Wakefield AJ. 2000. Early determinants of inflammatory bowel disease: use of two national longitudinal birth cohorts. *Eur J Gastroenterol Hepatol* 12(1):25-30.
- Rec# 209. Trottier G, Srivastava L, Walker CD. 1999. Etiology of infantile autism: a review of recent advances in genetic and neurobiological research. *J Psychiatry Neurosci* 24(2):103-15.
- Rec# 504. U.S. House of Representatives Committee on Government Reform. 2000. Autism - Present challenges, Future Needs - Why the Increased Rates? [Online]. Available: <http://www.house.gov/reform/hearings/healthcare/00.06.04/index.htm> [accessed December, 2000].
- Rec# 790. UK Department of Health. March 12, 1998. MMR-parents' concerns and media interest; Message from Sir Kenneth Calman, Chief Medical Officer, Department of Health . [Online]. Available: <http://www.doh.gov.uk/cmo.cmo986.html> [accessed January 31, 2001].
- Rec# 469. VAERS Reports. *Made Available to IOM Immunization Safety Review Committee*; 2001.
- Rec# 461. Volkmar F. Presentation to Immunization Safety Review Committee. Diagnosis of Autism: March 8, 2001; Washington, DC.
- Rec# 370. Volkmar FR, Lord C. 1998. Diagnosis and definition of autism and other pervasive developmental disorders. Volkmar FR, Editor. *Autism and Pervasive Developmental Disorders*. Cambridge: Cambridge University Press.
- Rec# 325. Wakefield AJ, Ekobom A, Dhillon AP, Pittilo RM, Pounder RE. 1995. Crohn's disease: pathogenesis and persistent measles virus infection. *Gastroenterology* 108(3):911-6.
- Rec# 115. Wakefield AJ, Montgomery SM. 1999. Autism, viral infection and measles-mumps-rubella vaccination. *Isr Med Assoc J* 1(3):183-7.
- Rec# 423. Wakefield AJ, Montgomery SM. 2000. Measles, mumps, rubella vaccine: through a glass, darkly. *Adverse Drug React Toxicol Rev* 19(4):265-83; discussion 284-92.
- Rec# 120. Wakefield AJ, Montgomery SM, Pounder RE. 1999. Crohn's disease: the case for measles virus. *Ital J Gastroenterol Hepatol* 31(3):247-54.
- Rec# 273. Wakefield AJ, Pittilo RM, Sim R, et al. 1993. Evidence of persistent measles virus infection in Crohn's disease. *J Med Virol* 39(4):345-53.
- Rec# 443. Wakefield AJ. Presentation to Immunization Safety Review Committee. March 8, 2001; Washington DC. 2001.
- Rec# 101. Wakefield AJ, Anthony A, Murch SH, et al. 2000. Enterocolitis in children with developmental disorders [see comments]. *Am J Gastroenterol* 95(9):2285-95.
- Rec# 41. Wakefield AJ, Murch SH, Anthony A, et al. 1998. Ileal-lymphoid-nodular hyperplasia, non-specific colitis,

and pervasive developmental disorder in children. *Lancet* 351(9103):637-641.

Rec# 404. Ward B, DeWals P. 1997. Association between measles infection and the occurrence of chronic inflammatory bowel disease. *Can Commun Dis Rep* 23(1):1-5; discussion 5-6.

Rec# 493. Watson M. Letter to Immunization Safety Review Committee. 2001 Mar 6.

Rec# 507. Waxman H. Letter to Honorable Donna L. Shalala, Secretary of Health. 2000 May 22.

Rec# 172. Webb EV, Lobo S, Hervas A, Scourfield J, Fraser WI. 1997. The changing prevalence of autistic disorder in a Welsh health district. *Dev Med Child Neurol* 39(3):150-2.

Rec# 44. White CC, Koplan JP, Orenstein WA. 1985. Benefits, risks and costs of immunization for measles, mumps and rubella. *AJPH* 75(7):739-744.

Rec# 3. Wing L. 1993. The definition and prevalence of autism. A review. *Eur Child Adolesc Psychiatr* 2:61-74.

Rec# 93. Wing L. 1996. Autistic spectrum disorders [editorial]. *BMJ* 312(7027):327-8.

Rec# 191. Wing L, Yeates SR, Brierley LM, Gould J. 1976. The prevalence of early childhood autism: comparison of administrative and epidemiological studies. *Psychol Med* 6(1):89-100.

Rec# 467. Woo J. Presentation to Immunization Safety Review Committee. Autism Reports to VAERS: March 8, 2001; Washington, DC.

Rec# 511. Yazbak FE. January 26, 2001. Dr. Salisbury: You are wrong on every point! [Online]. Available: <http://www.whale.to/v/yazbak1.html> [accessed March 7, 2001].